Harald Enzmann

1.8k total citations
88 papers, 1.1k citations indexed

About

Harald Enzmann is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Harald Enzmann has authored 88 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Molecular Biology and 13 papers in Surgery. Recurrent topics in Harald Enzmann's work include Allergic Rhinitis and Sensitization (10 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Metabolism, Diabetes, and Cancer (8 papers). Harald Enzmann is often cited by papers focused on Allergic Rhinitis and Sensitization (10 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Metabolism, Diabetes, and Cancer (8 papers). Harald Enzmann collaborates with scholars based in Germany, Netherlands and Spain. Harald Enzmann's co-authors include Peter Bannasch, Doris Mayer, Ashish Shukla, Spiros Vamvakas, Marco Cavaleri, Francesco Pignatti, Emer Cooke, Alexander Hermani, Jean Grisouard and Sabine M. J. M. Straus and has published in prestigious journals such as The Lancet, Nature Reviews Drug Discovery and Environmental Health Perspectives.

In The Last Decade

Harald Enzmann

82 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harald Enzmann Germany 20 364 235 203 163 150 88 1.1k
R. M. Lowenthal Australia 20 251 0.7× 319 1.4× 101 0.5× 108 0.7× 266 1.8× 58 1.5k
Benjamin Lang United States 21 503 1.4× 99 0.4× 91 0.4× 58 0.4× 131 0.9× 62 1.5k
Lorraine Pelosof United States 16 371 1.0× 694 3.0× 224 1.1× 50 0.3× 161 1.1× 35 1.8k
Emmanouil Saloustros Greece 20 582 1.6× 594 2.5× 312 1.5× 85 0.5× 154 1.0× 71 1.6k
Lingbin Du China 15 252 0.7× 340 1.4× 194 1.0× 210 1.3× 204 1.4× 64 1.1k
François Collin United States 13 357 1.0× 150 0.6× 218 1.1× 25 0.2× 68 0.5× 28 868
José F. Leis United States 31 690 1.9× 776 3.3× 50 0.2× 74 0.5× 90 0.6× 159 3.2k
Stephen M. Schleicher United States 19 609 1.7× 373 1.6× 171 0.8× 43 0.3× 93 0.6× 62 1.3k
Yuting Tan China 17 422 1.2× 216 0.9× 114 0.6× 24 0.1× 88 0.6× 84 1.1k
Dingli Song China 14 371 1.0× 429 1.8× 283 1.4× 171 1.0× 117 0.8× 33 1.2k

Countries citing papers authored by Harald Enzmann

Since Specialization
Citations

This map shows the geographic impact of Harald Enzmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harald Enzmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harald Enzmann more than expected).

Fields of papers citing papers by Harald Enzmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harald Enzmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harald Enzmann. The network helps show where Harald Enzmann may publish in the future.

Co-authorship network of co-authors of Harald Enzmann

This figure shows the co-authorship network connecting the top 25 collaborators of Harald Enzmann. A scholar is included among the top collaborators of Harald Enzmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harald Enzmann. Harald Enzmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Delgado, Julio, Camille Vleminckx, Jonas Bergh, et al.. (2021). The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer. ESMO Open. 6(2). 100074–100074. 12 indexed citations
2.
3.
Tzogani, Kyriaki, Helga Haugom Olsen, Mats Ökvist, et al.. (2020). The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with anFLT3Mutation. The Oncologist. 25(7). e1070–e1076. 15 indexed citations
4.
Tzogani, Kyriaki, Karri Penttilä, Johanna Lähteenvuo, et al.. (2020). EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma. The Oncologist. 26(1). 70–76. 32 indexed citations
5.
Ponzano, Stefano, et al.. (2017). Promoting Safe Early Clinical Research of Novel Drug Candidates: A European Union Regulatory Perspective. Clinical Pharmacology & Therapeutics. 103(4). 564–566. 3 indexed citations
6.
Enzmann, Harald. (2016). New trends and challenges in the European regulation of innovative medicines. Regulatory Toxicology and Pharmacology. 80. 314–320. 7 indexed citations
7.
Mayer, P., et al.. (2011). Glitazone‐like action of glimepiride and glibenclamide in primary human adipocytes. Diabetes Obesity and Metabolism. 13(9). 791–799. 7 indexed citations
8.
Sommer, Andreas, Margarita Fuhrmann, P. Mayer, et al.. (2010). Characterization of proliferative effects of insulin, insulin analogues and insulin-like growth factor-1 (IGF-1) in human lung fibroblasts. Naunyn-Schmiedeberg s Archives of Pharmacology. 382(5-6). 511–524. 22 indexed citations
9.
Shukla, Ashish, Jean Grisouard, Volker Ehemann, et al.. (2009). Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocrine Related Cancer. 16(2). 429–441. 101 indexed citations
10.
Mayer, Doris, Ashish Shukla, & Harald Enzmann. (2008). Proliferative effects of insulin analogues on mammary epithelial cells. Archives of Physiology and Biochemistry. 114(1). 38–44. 62 indexed citations
11.
McCabe, Christopher, Lothar Bergmann, Nicholas Bosanquet, et al.. (2008). Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Annals of Oncology. 20(3). 403–412. 52 indexed citations
12.
Enzmann, Harald & Johannes Lütz. (2008). Förderung von Arzneimitteln für seltene Leiden durch die Europäische Gemeinschaft. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 51(5). 500–508. 7 indexed citations
13.
Iatropoulos, Michael J., et al.. (2001). Bioassay of mannitol and caprolactam and assessment of response to diethylnitrosamine in heterozygous p53 -deficient (+/-) and wild type (+/+) mice. Archives of Toxicology. 75(1). 52–58. 11 indexed citations
14.
Iatropoulos, Michael J., et al.. (2001). Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of moxifloxacin, a quinolone antibiotic. Experimental and Toxicologic Pathology. 53(5). 345–358. 8 indexed citations
15.
Gastpar, H, et al.. (1993). Intranasal treatment of perennial allergic rhinitis. Comparison of azelastine nasal spray and budesonide nasal aerosol.. PubMed. 43(4). 475–9. 14 indexed citations
16.
Enzmann, Harald, et al.. (1991). Die Diagnose des „excited-skin-syndrome” aus dem Blut. Laryngo-Rhino-Otologie. 70(4). 184–186. 2 indexed citations
17.
Enzmann, Harald, J. Mollenhauer, & Kay Brune. (1990). Humoral autoimmunity to cartilage in rheumatoid arthritis?. Inflammation Research. 29(1-2). 114–116. 3 indexed citations
18.
Enzmann, Harald, et al.. (1989). Unusual histochemical pattern in preneoplastic hepatic foci characterized by hyperactivity of several enzymes. Virchows Archiv B Cell Pathology Including Molecular Pathology. 57(1). 99–108. 22 indexed citations
19.
Enzmann, Harald, et al.. (1988). Elevation of Glucose-6-Phosphate in Early Stages of Hepatocarcinogenesis Induced in Rats by N-Nitrosomorpholine. Hormone and Metabolic Research. 20(2). 128–129. 8 indexed citations
20.
Enzmann, Harald. (1974). Diagnostische M�glichkeiten der Rhinorheomanometrie bei perennialen Rhinitiden. European Archives of Oto-Rhino-Laryngology. 207(2). 576–577. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. M. Lowenthal Breakdown of academic impact, for papers by Benjamin Lang Breakdown of academic impact, for papers by Lorraine Pelosof Breakdown of academic impact, for papers by Emmanouil Saloustros Breakdown of academic impact, for papers by Lingbin Du Breakdown of academic impact, for papers by François Collin Breakdown of academic impact, for papers by José F. Leis Breakdown of academic impact, for papers by Stephen M. Schleicher Breakdown of academic impact, for papers by Yuting Tan Breakdown of academic impact, for papers by Dingli Song
Rankless by CCL
2026